This federal contract award to RLS (USA) Inc., a foreign-owned, for-profit radiopharmacy company, has an award value of $342,124.50. The contract is for the delivery of radiopharmaceuticals such as gallium-67, fluorodeoxyglucose F-18, thallium-201, technetium-99m, and Gallium-68 Dotatate to support nuclear medicine diagnostic services at U.S. Department of Veterans Affairs (VA) medical centers and military treatment facilities. The contract has an ultimate completion date of March 31, 2026.
RLS (USA) Inc. holds several federal contract Indefinite Delivery Vehicles (IDVs) with the VA and Defense Health Agency (DHA) to facilitate the efficient procurement of its radiopharmaceutical products. These IDVs include a $4,998,603.38 contract with VA VISN 17 for radiopharmaceuticals, a $538,493.10 small business set-aside contract with VA VISN 2 for Netspot (Gallium-68 dotatate), and a $1,914,116.40 contract with the DHA for general radiopharmaceuticals. The IDVs typically have performance periods of three to five years.
Generated 4/2/25, 9:46 AM